ALLIANCE PHARMA PLC

AGM Information • May 18, 2022

National Storage Mechanism | Additional information

RNS Number : 8507L

Alliance Pharma PLC

18 May 2022

For immediate release	18 May 2022

ALLIANCE PHARMA

("Alliance" or the "Group")

AGM statement

Alliance Pharma plc (AIM: APH), the international healthcare group, will hold its Annual General Meeting ("AGM") at 10:00am this morning. At the meeting, the Group's Chair, David Cook, will make the following statement:

"Firstly, on behalf of the Alliance Board, I would like to take this opportunity to thank Alliance's employees around the world for their continued commitment and support.

"The overall business is in good health and consumer demand for our brands remains strong. The integration of ScarAway and the rights to Kelo-cote in the US (acquired in March 2022) is progressing well.

"In line with the comments made at the FY 2021 results in March 2022, we continue to expect FY 2022 performance to be weighted to H2 due to our anticipated sales trajectory for Amberen and Nizoral, together with temporary disruption to our supply chain through COVID-related lockdowns in China, which is now beginning to ease.

"We remain confident in our ability to deliver full year financial performance in line with market expectations. Further commentary on our first half trading performance will be provided in our trading update in July 2022."

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Cora McCallum, Head of Investor Relations & Corporate Communications	+ 44 (0)1249 705168
ir@allianceph.com
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff
alliancepharma@buchanan.uk.com
Numis Securities Limited	+ 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield / Duncan Monteith
Corporate Broking: James Black
Investec Bank plc	+ 44 (0)20 7597 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGMBKOBNOBKDKPD